TAI PING CARPET(00146)公布截至2025年12月31日止6个月中期业绩，收益约3.09亿港元，同比增长 0.36%;公司拥有人应占溢利1968.6万元，同比减少9.27%;每股溢利9.28港仙。 ...

国际家居零售(01373)发布公告，于2026年2月11日斥资10.8万港元回购15万股。 ...

该信息由智通财经网提供 智通财经APP讯，十月稻田(09676)发布公告，于2026年2月11日，该公司斥资424.97万港元回购48.69万 股股份，每股回购价8.44-8.91港元。 ...

Core Viewpoint - The strategic cooperation agreement between Zhongsheng Beikong Biotechnology (08247) and Xiaoshou Medical aims to enhance the capacity of grassroots medical services and promote the distribution of quality medical resources [1] Group 1: Capital and Strategic Collaboration - The company plans to make a strategic investment in Xiaoshou Medical to establish a long-term stable partnership and explore innovative development models in the grassroots medical market [2] Group 2: Business and Resource Complementation - The company will leverage its advantages in in vitro diagnostics (IVD) products and R&D capabilities, combined with Xiaoshou Medical's nationwide grassroots medical channel network and digital platform, to deliver biochemical, immunological, and POCT products directly to grassroots medical institutions [3] - A joint working group will be established to enhance data insights, product development, and supply chain optimization while developing customized products and "smart testing solutions" suitable for grassroots medical scenarios [3] Group 3: Ecosystem and Value Co-Creation - The collaboration will integrate various resources such as equipment, reagents, operations, and data to provide one-stop testing service solutions for regional medical communities and chain clinics, thereby improving the overall testing capabilities and operational efficiency of grassroots medical institutions [4] - The cooperation will be implemented in phases, starting with strategic pilot verification and gradually expanding to large-scale implementation, while exploring deeper collaboration at the industrial and capital levels [4] - The board believes that this strategic cooperation will help the company integrate quality R&D capabilities with digital channel resources, accelerating the penetration of products and services into grassroots medical institutions, aligning with national initiatives to enhance the grassroots medical system and the "Healthy China" strategy [4]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval was granted to Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd. [1] - The company has invested approximately RMB 1.5 million in research and development for Tamsulosin hydrochloride [1] - The drug is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] Group 2: Regulatory and Market Implications - The approval indicates that the raw material meets the regulatory requirements for domestic drug registration, allowing it to be sold in the domestic market [1] - This experience will be valuable for the company in future raw material drug applications [1] - The approval is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The core viewpoint of the announcement is the strategic cooperation agreement between China National Pharmaceutical Group (中生北控生物科技) and Guangdong Xiaoshou Medical Technology, aimed at enhancing grassroots medical services and resource allocation [1][2][3] Group 2 - The cooperation will involve capital and strategic synergy, with the company planning to make a strategic investment in Xiaoshou Medical to establish a long-term partnership and explore innovative development models in the grassroots medical market [1][2] - The collaboration will leverage the company's strengths in in vitro diagnostics (IVD) and Xiaoshou Medical's extensive grassroots medical network and digital platform to deliver biochemical, immunological, and POCT products directly to grassroots medical institutions [2] - The partnership aims to create a one-stop testing service solution for regional medical communities and chain clinics by integrating various resources, thereby improving the overall testing capabilities and operational efficiency of grassroots medical institutions [3]

上述合同的正常履行，预计将对公司未来的业绩产生积极影响，有利于提高公司中长期市场竞争力和盈 利能力，进一步巩固公司的市场竞争优势。 *ST松发（603268）(603268.SH)发布公告，公司下属公司恒力造船(大连)有限公司(简称"恒力造船")15 艘30.6万吨超大型原油运输船建造合同于近日签约生效。合同金额合计约17-20亿美元。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced the election of Mr. Zhao Yong as the employee director of the company's eighth board of directors during the second joint meeting of the third employee representative assembly scheduled for February 11, 2026 [1] Group 1 - Mr. Zhao Yong was elected as the employee director of the eighth board of directors [1] - The election was conducted in accordance with the company's shareholder meeting procedures [1] - Mr. Zhao's term will last from the date of election until the end of the eighth board's term [1]

中国金融投资管理(00605)发布公告，于2026年2月11日，本公司控制的非全资附属公司成都惠信小贷(作 为贷款人)与客户FP及客户FQ(作为借款人)订立贷款协议，成都惠信小贷同意向借款人授出本金金额为 人民币800万元的贷款，期限为一年。 ...

兴证国际(06058)发布公告，于2026年2月11日，本公司(作为借款方)与若干金融机构(作为贷款方)就2.58 亿美元及20亿港元的循环贷款订立为期364天的融资协议。 ...